Comparative Pharmacology
Head-to-head clinical analysis: LEVO T versus THYROLAR 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVO T versus THYROLAR 1.
LEVO-T vs THYROLAR-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic form of thyroxine (T4), a thyroid hormone. It is deiodinated to triiodothyronine (T3), which binds to nuclear thyroid hormone receptors, resulting in modulation of gene transcription and increased metabolic rate.
Thyrolar-1 is a combination of levothyroxine (T4) and liothyronine (T3). T4 is converted to the active hormone T3 in peripheral tissues. Both forms bind to thyroid hormone receptors, which regulate gene transcription, influencing metabolism, growth, and development.
1.6 mcg/kg orally once daily (typical adult starting dose 50-100 mcg/day); adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH.
Oral: 30-60 mg liothyronine (T3) daily, typically initiated at 15 mg/day and titrated upward based on clinical response. Usual maintenance dose 25-50 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days in euthyroid individuals; in hyperthyroidism, half-life shortens to 3-4 days; in hypothyroidism, it prolongs to 9-10 days. The long half-life supports once-daily dosing.
Levothyroxine (T4): 6–7 days; Liothyronine (T3): 1–2 days. In hyperthyroidism, T4 half-life may be reduced to 3–4 days; in hypothyroidism, prolonged to 9–10 days.
Renal: ~20-40% of administered levothyroxine is excreted in urine as unchanged drug and conjugates; biliary/fecal: ~40-60% is excreted in feces via bile, largely as conjugates and minor amounts of unchanged drug.
Renal excretion of iodide; after deiodination of T3 and T4, iodine is excreted in urine (∼80%) and feces (∼20%).
Category C
Category C
Thyroid Hormone
Thyroid Hormone